Suppression of gch1 sensitizes ovarian cancer and breast cancer to parp inhibitor

HIGHLIGHTS

• who: Siyuan Wang and collaborators from the Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Jiefang Ave, Wuhan, China have published the research: Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor, in the Journal: Journal of Oncology of 20/09/2022
• what: The authors focused on GCH1, which had a relatively signifcant diference. In the past decades, there has been a great increase in the number of preclinical studies focusing on approaches that could strengthen the PARP inhibitors` cytotoxicity. Although the authors propose a rational therapeutic strategy to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.